Scarica l'app Stockscreener
212.56
0.21%
-0.44
Dopo l'orario di chiusura:
212.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie’s Latest Study on Parkinson’s Treatment: What Investors Need to Know - TipRanks
AbbVie’s New Study on Risankizumab: A Potential Game-Changer for Ulcerative Colitis? - TipRanks
How to use a screener to detect AbbVie Inc. breakoutsGap Down & Verified Momentum Stock Watchlist - Newser
AbbVie (ABBV) Declares US$1.64 Quarterly Dividend for Shareholders - Yahoo Finance
AbbVie’s Phase 3b Study on Elagolix: A Potential Game-Changer for Endometriosis Treatment? - TipRanks
AbbVie declares quarterly dividend of $1.64 per share By Investing.com - Investing.com South Africa
Is AbbVie Inc. a good stock for dollar cost averaging2025 Sector Review & Fast Exit and Entry Strategy Plans - خودرو بانک
Verizon, Essex Property Trust, Broadcom, Sachem Capital, AbbVie, Nucor Announce Dividend Increases - AInvest
Abbvie Inc. Declares Quarterly Dividend, Payable on November 14, 2025 - MarketScreener
AbbVie Inc. Announces Quarterly Dividend of $1.64 per Share - AInvest
AbbVie Incdeclares quarterly dividend of $1.64 per share - MarketScreener
Is AbbVie Inc. stock undervalued right nowQuarterly Risk Review & Entry Point Strategy Guides - خودرو بانک
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie declares quarterly dividend of $1.64 per share - Investing.com
AbbVie Keeps Quarterly Dividend at $1.64 a Share, Payable Nov. 14 to Shareholders of Record as of Oct. 15 - MarketScreener
Will AbbVie Inc. outperform the market in YEARGold Moves & Low Risk Growth Stock Ideas - خودرو بانک
Stock Analysis | Abbvie OutlookTechnical Neutrality and Strong Fundamentals Amid Mixed Analyst Ratings - AInvest
AbbVie Inc. Added to Custom Quant Screener TodayJuly 2025 Decliners & Weekly Top Performers Watchlists - Newser
Intraday pattern recognizer results for AbbVie Inc.Sell Signal & Capital Efficiency Focused Ideas - Newser
AbbVie Inc. (NYSE:ABBV) Is a Favorite Amongst Institutional Investors Who Own 74% - 富途牛牛
AbbVie’s ABBV-400 Study: A New Hope for Advanced Solid Tumors - TipRanks
AbbVie’s New Study on Risankizumab: Implications for Psoriatic Arthritis Treatment - TipRanks
Opinions September 4, 2025 - The Indiana Lawyer
AbbVie’s Real-World Study on Epcoritamab: A Potential Game-Changer in Lymphoma Treatment - TipRanks
AbbVie Advances Pediatric Infection Treatment with New Clinical Study - TipRanks
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? - sharewise.com
Is AbbVie Inc. stock overvalued or fairly pricedJuly 2025 Update & Verified Chart Pattern Signals - خودرو بانک
AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial - Yahoo Finance
Health Canada approves AbbVie’s Elahere for ovarian cancer - Yahoo Finance
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? - The Motley Fool
Is AbbVie Stock Underperforming the S&P 500? - MSN
7th Circ. Backs AbbVie's Win Against Ex-Sales Rep's FCA Suit - Law360
AbbVie’s $0.84 Billion Volume Tumbles to 100th as Regulatory Uncertainty and Biosimilar Delays Weigh on Investor Sentiment - AInvest
Genmab/AbbVie’s Epkinly Could Get Competitive Edge With Outpatient Option - insights.citeline.com
AbbVie Beats Employee’s Would-Be Whistleblower Suit on Appeal - Bloomberg Law News
AbbVie (ABBV) Advances Cancer Treatments With Epcoritamab And Mirvetuximab Approvals - Yahoo Finance
Will AbbVie Inc. bounce back from current supportEarnings Risk Summary & High Accuracy Trade Signal Alerts - Newser
AstraZeneca attorney says state 340B laws will ‘topple’ the federal drug discount program - Endpoints News
AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting - Seeking Alpha
AbbVie reports positive results for outpatient lymphoma treatment - Investing.com
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Investing News Network
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - PR Newswire
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers - AbbVie News Center
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Quantitative breakdown of AbbVie Inc. recent moveTrade Signal Summary & Daily Profit Maximizing Tips - Newser
Combining machine learning predictions for AbbVie Inc.Stop Loss & Fast Gaining Stock Strategy Reports - Newser
AbbVie’s Strategic Acquisitions and Trial Success Fuel 0.72% Rally Despite 102nd-Ranked 920M Volume - AInvest
Is AbbVie Inc. impacted by rising ratesRisk Management & Fast Exit and Entry Trade Guides - خودرو بانک
Strategic Implications of AbbVie’s Elahere Approval in Canada: A New Era for Oncology Growth and Market Access - AInvest
AbbVie's Elahere gains approval in Canada for ovarian cancer - Seeking Alpha
Visual trend scoring systems applied to AbbVie Inc.Trade Entry Summary & Real-Time Buy Zone Alerts - Newser
AbbVie HIV Drugs Being Tested as Possible Coronavirus Antidote - TheStreet
How does AbbVie Inc. compare to its peersWeekly Profit Report & Low Risk Entry Point Tips - خودرو بانک
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - Investing News Network
Candlestick signals on AbbVie Inc. stock today2025 Trade Ideas & Fast Gain Swing Alerts - Newser
AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market - MSN
Explore the human side of the health journey in AbbVie’s I Am campaign - Medical Marketing and Media
Visual analytics tools that track AbbVie Inc. performanceFed Meeting & Real-Time Sentiment Analysis - Newser
AbbVie to invest $195 million in new North Chicago pharmaceutical facility - Chicago Construction News
AbbVie (ABBV) Stock Analysis: Price Target & Market OutlookNews and Statistics - IndexBox
0.18%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):